Hyperlipoproteinemias Archives - MPR

Hyperlipoproteinemias

Vascepa sNDA Seeking Expanded Indication to Reduce Major CV Events

Amarin has submitted a supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl) to reduce the risk of major cardiovascular (CV) events in the statin-treated population. Icosapent ethyl is a single-molecule consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. It is currently indicated as an adjunct to diet to reduce triglyceride…